The global abdominal pain drugs market size was valued at USD 89.39 billion in 2024 and is expected to reach USD 131.06 billion by 2032, at a CAGR of 4.90% during the forecast period
The market growth is largely fueled by the increasing prevalence of gastrointestinal disorders, irritable bowel syndrome (IBS), and other abdominal pain–related conditions, driving higher demand for effective treatment options
Furthermore, growing patient awareness, the development of novel drug formulations, and the rising adoption of over-the-counter as well as prescription medications are establishing abdominal pain drugs as a critical segment in gastrointestinal therapeutics. These converging factors are accelerating the uptake of Abdominal Pain Drugs solutions, thereby significantly boosting the industry's growth